Pregnancy and Valproate Exposure in Focal Epilepsy
28-year-old woman at 10 weeks' gestation with left temporal cavernoma-related focal epilepsy presents because of three focal impaired awareness seizures and one secondarily generalized seizure in the past 3 weeks. She has been seizure-free for 4 years on valproate 1000 mg/day. She did not attend her prenatal visit and remains on valproate; she reports morning nausea and poor sleep but no fever. EEG shows left temporal spikes; MRI shows a stable 1.5-cm cavernoma with no new hemorrhage. Blood pressure is 112/70 mmHg, BMI 31, and she takes no other medications. She has no family history of neural tube defects and no prior pregnancy. She wants to continue the pregnancy and asks whether she can simply lower the valproate dose until delivery. Her obstetrician has not yet been told about the epilepsy history.
1. What is the risk of continuing valproate, and how should her antiseizure medication be changed during pregnancy?
Read the worked answer
Valproate is the most teratogenic commonly used antiseizure medication. It carries a dose-dependent risk of neural tube defects, cardiac and skeletal malformations, and adverse neurodevelopmental outcomes, including lower IQ and autism spectrum disorder. At 1000 mg/day and 10 weeks' gestation, the fetus has already been exposed during neural tube closure, but exposure continues and the risk remains important. Simply lowering the dose is not adequate because seizure control is already worsening and lower dose does not eliminate teratogenicity.
She needs an urgent epilepsy-obstetric plan. Do not stop valproate abruptly. Transition to a pregnancy-preferred agent - lamotrigine or levetiracetam - with overlap and slow titration while monitoring seizures. Lamotrigine clearance rises substantially in pregnancy, so levels must be checked frequently; levetiracetam levels also fall. Start folic acid 5 mg daily now. Arrange maternal-fetal medicine and neurology co-management, and document that she was counseled about risks and that abrupt withdrawal could provoke status epilepticus.
2. She has a convulsive seizure lasting more than 5 minutes at 20 weeks. What is the acute management?
Read the worked answer
Treat as convulsive status epilepticus. Give intravenous lorazepam 4 mg (or midazolam if no IV access); repeat once after 5–10 minutes if seizures persist. Because she is pregnant, protect the airway, give oxygen, position her left lateral, check glucose, and monitor fetal heart rate after maternal stabilization.
If seizures continue, give a second-line intravenous antiseizure medication: levetiracetam 60 mg/kg (maximum 4500 mg) or fosphenytoin 20 mg phenytoin equivalents/kg. Avoid valproate as the second-line agent if an alternative exists. Refractory status requires intubation and continuous EEG; propofol, midazolam, or ketamine can be used with obstetric and critical-care input. Magnesium is not the treatment for focal-onset status. After control, identify triggers such as sleep deprivation, nausea-related nonadherence, or cavernoma hemorrhage.
3. What monitoring and delivery counseling should she receive?
Read the worked answer
Monitor antiseizure medication levels at least monthly and after dose changes, because pregnancy alters clearance and adherence. Track seizure frequency; recurrent seizures increase maternal trauma and obstetric risk. Continue folic acid, check hemoglobin and iron, and involve maternal-fetal medicine for fetal anatomy scanning and growth surveillance.
Delivery should occur at a center with neonatal and obstetric capability. Most women with epilepsy can have vaginal delivery; epidural analgesia is not contraindicated. Continue antiseizure medication through labor to avoid withdrawal seizures. If she remains on an enzyme-inducing drug near delivery, consider neonatal vitamin K prophylaxis per local protocol, though this is most relevant for enzyme inducers. Counsel her that postpartum sleep deprivation and medication changes can lower seizure threshold, and arrange early neurology follow-up.